Gilead Sciences raised its full-year HIV sales growth guidance to 9-10% from 8%, driven by a $4-billion annualized PrEP business and continued strong performance of Biktarvy. The company expects Yeztugo sales to reach approximately $1 billion in 2026, signaling blockbuster potential in its first full year on the market. The FDA accepted Gilead's new drug application for bictegravir/lenacapavir under priority review with a target action date of Aug. 27, 2026. Gilead and Merck announced positive phase III results from the ISLEND-1 and ISLEND-2 studies for a once-weekly oral combination of islatravir and lenacapavir, which will form the basis of regulatory submissions. Gilead's shares have gained 13.2% year to date, and the stock currently carries a Zacks Rank #3 (Hold).
Gilead Sciences IncRaised HIV sales growth guidance to 9-10% driven by strong PrEP and Biktarvy performance.
Merck & Company IncPositive phase III results for islatravir/lenacapavir combination with Gilead, supporting regulatory submissions.
GSK plc
Merck KGaA